Navigation Links
REMstar Plus

ProductsREMstar Plus
Company Respironics, Inc.
Item REMstar Plus
Features 
  • Hour/Session meter accumulates usage sessions greater than 4 hours and total hours used
  • Ramp capabilities allow a 0 - 45 minute time period with a patient-adjustable ramp start pressure
  • Lighted patient buttons are located on the CPAP unit to control it and the heated humidifier
  • Carrying case offers padding and is big enough to carry both the CPAP unit, mask and heated humidifier
  • International power supply with power cord
  • Icon-based display makes set-up easy
  • Pressure calibration key allows you to target pressure setting to within 0.1 cm H2O
  • Integrated handle for transport
  • 3-position altitude compensation
  • Quiet operation
  • DC operation
  • Washable pollen filters and optional ultra-fine filters
  • 2-year warranty
Description This unit offers a display, ramp capabilities and integrated humidification controls. It also has features that make set-up easy and accurate. Its session meter records the number of sessions that last more than four hours - giving you insight into patients' daily usage patterns.
Info Respironics, Inc.
Customer Service: (800) 345-6443
Web site: http://www.respironics.com

Related medicine products :

1. REMstar Pro with C-Flex
2. REMstar Plus with C-Flex
3. REMstar® Auto with C-Flex™
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products:
(Date:12/6/2009)... avoid oysters harvested from San Antonio Bay ,, ... Food and Drug Administration is advising consumers to avoid ... or after Nov. 16 due to reports of norovirus-associated ... from this area, which is located on the Gulf ... ) ,, The FDA, along with the Centers for ...
(Date:12/6/2009)... by researchers from the Medical College of Wisconsin, in ... pain and other sickle cell disease complications in children. ... providers and patients were also identified. The study ... of pediatrics at the Medical College and Children,s Research ... presented at the American Society of Hematology meeting Dec. ...
(Date:12/6/2009)... www.sleeping-with-a-sleeping-disorder.com is asking people ,who have ... aids from around the world to donate their ... submissions will be compiled in an ebook titled ... be sold from the website in early January ... proceeds ,from sales of the E-book to three ...
(Date:12/5/2009)... Dec. 5 ,, What: Cuts for ... difference in the fight against cancer and other terminal illnesses ... be donated to St. Jude Children,s Research Hospital. Guests will ... a delectable and savory Vietnamese restaurant in Falls Church for ...
(Date:12/5/2009)... Research debunks the ,something,s wrong with being single, myth , , ... people who pass their 40th birthday without ever tying the ... health woes than married folks. And, um, isn,t there something ... so fast. , A new study looking at psychological measures ...
Breaking Medicine News(10 mins):Health News:FDA, CDC, and States Investigating Norovirus Illnesses Linked to Oysters 2Health News:New study finds barriers to pain treatment in children with sickle cell disease 2Health News:Donate a Herbal Natural Sleep Aid to the Internet's First "Natural Sleep Aids E-book" Written by People Just Like You 2Health News:Never Married, Over 40, Well-Adjusted 2Health News:Never Married, Over 40, Well-Adjusted 3
... in a large-scale, multi-center trial of patients with acute ... showed that higher levels of// nitric oxide (NO) in ... It also showed more ventilator-free days, and decreased rates ... ,The results appear in the first issue for February ...
... sports in the world, has continued to grow in ... children participating in organized and// unorganized soccer leagues increases, ... injury. A study conducted by researchers in the Center ... Hospital is the first comprehensive look at the total ...
... to hair dye are increasing as more and younger people ... to dermatitis on the face and, in severe cases, facial ... hair dyes currently contain para-phenylenediamine (PPD) and other related agents. ... a serious problem that it was banned from hair dyes ...
... the war against the lard, a new weapon is being ... a baby food ingredient -oligo fructose, on obese human subjects. ... showed the natural fiber seen in baby foods, cereals and ... ,Reportedly, oligo fructose increased the amounts of a ...
... care workers sleepless nights.// ,There has been an accounting of ... in King County, Seattle. ,This form of AIDS progresses ... treat. ,Health officials have confirmed this same strain of virus ... also methamphetamine users having multiple sex partners. ,It is ...
... An intervention to improve communication between clinicians in the ... dying patient significantly reduces feelings of stress,// anxiety, and ... that appears in the February 1, 2007 issue of ... ,The study, funded in part by the National Institute ...
Other Medicine News:Health News:NO Linked With Increased Survival in ALI/ARDS 2Health News:Study Reveals 1.6 Million Pediatric Soccer Injuries 2Health News:Communication in the ICU to Be Strengthened 2Health News:Communication in the ICU to Be Strengthened 3
(Date:12/4/2009)... MORRISTOWN, N.J., Dec. 4 Watson Pharmaceuticals, Inc. (NYSE: ... company, today confirmed that its subsidiary, Watson Laboratories, Inc.-Florida, ... U.S. Food and Drug Administration seeking approval to market ... a patent owned by Takeda Pharmaceutical Company Limited. ...
(Date:12/4/2009)... Dec. 4 Drs. Neal Shore and E. David ... the additional analysis of secondary end points of biochemical ... FIRMAGON® (monthly degarelix for injection) or monthly leuprolide in ... Prostate cancer patients who received FIRMAGON 240/80 mg/month ...
(Date:12/4/2009)... AZN ) today announced that the US Food ... (quetiapine fumarate) Extended Release Tablets as adjunctive (add-on) treatment ... SEROQUEL XR is the only medication in its class ... disorder as adjunctive therapy and acute depressive episodes associated ...
Breaking Medicine Technology:Watson Files FDA Application for Generic Rozerem(R) 2Watson Files FDA Application for Generic Rozerem(R) 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9U S Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON 28R 29 for Malignant Melanoma 14672 1U S Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON 28R 29 for Malignant Melanoma 14672 2U S Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON 28R 29 for Malignant Melanoma 14672 3U S Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON 28R 29 for Malignant Melanoma 14672 4U S Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON 28R 29 for Malignant Melanoma 14672 5U S Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON 28R 29 for Malignant Melanoma 14672 6BioSpecifics Technologies Corp to Host Conference Call to Report Third Quarter 2009 Financial Results on November 5 2009 14669 1BioSpecifics Technologies Corp to Host Conference Call to Report Third Quarter 2009 Financial Results on November 5 2009 14669 2Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 1Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 2Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 3Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 4Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 5Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 6Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 7